Reduced-dose pneumococcal schedules still generated strong memory B-cell immunity in infants
Reduced-dose pneumococcal conjugate vaccine schedules are meant to preserve protection while using fewer injections, and this preprint examines whether the immune memory they leave behind is still biologically durable. In Vietnamese infants, investigators compared 0+1 and 1+1 schedules of PCV10 and PCV13 and tracked serotype-specific memory B cells as a marker of longer-term immune readiness. The central question was not just whether antibody levels rose, but whether the immune system built the cellular memory needed to respond quickly to later pneumococcal exposure.
The design focused on randomised subsets of infants, with 50 per vaccine group per timepoint. Blood sampling occurred at 12 months of age at baseline, then again at day 7 and day 28 after vaccination. That timing matters because memory B-cell activation unfolds in phases: early expansion reflects rapid recall, while the later timepoint captures whether the response consolidates after the burst of plasmablast activity. The study used multimer spectral flow cytometry, a method suited to detecting serotype-specific cellular responses with precision rather than relying on antibody titres alone.
A single or two-dose schedule of either vaccine induced robust serotype-specific BMEM responses by day 7 and day 28 for most serotypes. Early after vaccination, the PCV13 arm produced higher and earlier B-cell memory responses than PCV10, and the 1+1 schedules outperformed the 0+1 schedules at day 7. By day 28, the gap between 0+1 and 1+1 schedules had faded. The immune system appeared to have caught up, but the early advantage of the booster-containing schedule suggests a faster building of recall-ready immunity after the second exposure.
PCV13 drove the earliest and strongest cellular responses
The difference between the two products was not limited to memory B cells. PCV13 also generated higher plasmablast and plasma cell responses by day 7, followed by higher circulating T follicular helper cell responses by day 28. Those cellular signals fit an immunologic sequence in which antigen presentation, germinal center help, and antibody-secreting cell expansion occur in a coordinated wave. A broader valency vaccine can expose the infant immune system to more serotypes, and the pattern here suggests that added breadth did not come at the cost of weaker cellular activation.
This is an important point for reduced-dose policy. WHO-endorsed 1+1 schedules are intended for specific settings where programmatic simplicity and vaccine supply matter. Cellular data of this kind help answer a question antibody titres alone cannot resolve: whether fewer priming doses still leave enough immune memory to respond rapidly when exposure returns. In this cohort, they did.
One striking finding stood out: serotypes 6B and 23F generated detectable BMEM responses even in infants who did not reach protective serotype-specific IgG levels of at least 0.35 µg/mL. That disconnect between measurable antibodies and cellular memory suggests that serologic cutoffs do not fully capture vaccine-induced immunity. A child can sit below a conventional antibody threshold and still retain a reservoir of antigen-specific memory B cells capable of rapid reactivation. For pneumococcal vaccination, that distinction has practical implications for how investigators interpret protection and how vaccine schedules are compared across studies.
Why memory B cells matter for long-term pneumococcal protection
Pneumococcal disease is driven by a large serotype burden, and vaccine performance depends on more than peak post-vaccination IgG. Memory B cells are the immune archive that can be reawakened on re-exposure, driving faster secondary responses and helping sustain protection after circulating antibody levels decline. In infants, whose immune systems are still developing, the ability to generate this compartment efficiently is especially relevant.
The schedule comparison also speaks to how infant priming shapes later immune architecture. A 1+1 strategy gives the immune system an early encounter at 2 months and a later reinforcing dose at 12 months, which may improve maturation of the B-cell compartment. The 0+1 schedule, by contrast, relies on a later single exposure at 12 months. The data suggest that both approaches can eventually induce substantial memory, but the booster-containing schedule creates a quicker and stronger early cellular response, at least for the first month after vaccination.
What this means for evaluation of PCV programs
These findings extend beyond the narrow question of which schedule raises antibody titres fastest. They support the idea that reduced-dose programs can still produce meaningful immunologic memory, even when protective IgG thresholds are not met for every serotype. They also show that PCV13 and PCV10 do not behave identically at the cellular level. PCV13 produced earlier and higher BMEM responses, greater plasmablast and plasma cell activity at day 7, and stronger cTfh responses by day 28, signaling a more vigorous early germinal center-linked response.
For public health programs, the relevance is straightforward: schedule selection should account for both serotype coverage and the quality of the immune memory left behind. For translational immunology, the study shows that memory B-cell assays can reveal vaccine effects that conventional serology may miss. For infants in settings where pneumococcal disease remains a serious threat, a reduced-dose strategy is not simply a matter of fewer injections; it is a question of whether the immune system is being trained in a way that can still support durable recall.
The work remains a preprint and has not been peer reviewed. Its strongest contribution is mechanistic rather than clinical: it shows that 1+1 schedules of PCV10 or PCV13 can generate robust serotype-specific memory B-cell responses, while PCV13 appears to create a stronger early cellular imprint. Longer follow-up will be needed to connect those cellular signals to persistence of protection and to determine how well these patterns track with real-world disease reduction across serotypes and schedules.